Volastra Therapeutics, a clinical-stage oncology company pioneering therapies targeting chromosomal instability (CIN), today ...

OncoHost, a technology company transforming precision oncology through proteomics-based biomarker development, today announced its acceptance to present a scientific poster at the American Association ...

Please provide your email address to receive an email when new articles are posted on . ADx NeuroSciences and Alamar Biosciences have announced a partnership to develop customized biomarker assays for ...

Protein biomarkers increasingly play a vital role in advancing health research, driving drug development, and improving clinical outcomes. The close connection between protein biomarkers and human ...

ViewsML, a company building the computational layer for biomarker discovery by transforming tissue analysis from a lab process into software, today announced the completion of an oversubscribed $4.9M ...

Validated biomarkers will help physicians identify patient subgroups that will benefit most from specific treatment ...

The Forum on Neuroscience and Nervous System Disorders hosted a public workshop on June 21-22, 2010, bringing together key stakeholders, to present promising current and emerging technologies with ...

Background: The Prognostic Lung Fibrosis Consortium (PROLIFIC) was formed to develop well-qualified assays suitable for use as prognostic biomarkers within the context of clinical trials for Idiopathic ...

BOSTON--(BUSINESS WIRE)--Genialis, the RNA biomarker company, today announced an extension of its collaboration with Debiopharm, a Swiss-based global biopharmaceutical company, to develop a predictive ...

Ibex Medical Analytics, the global leader in clinical-grade AI-powered pathology, today announced a significant expansion of its biopharma business. Building on its successful collaborations in ...

We’re in the midst of a paradigm shift in biomarker science. Once considered exploratory, biomarker signatures have evolved into strategic assets - tools that actively de-risk decision-making across ...